HomeAbout usProductsInvestor centreMedia centrePartneringCareers

Pipeline


Antisoma clinical development pipeline


Drug Indication Preclinical Phase I Phase II Phase III
AS1413 Secondary AML        
AS1411 AML        
DCAM's Auto-immune        

AS1413 (amonafide L-malate) is a DNA intercalator in phase III in secondary AML

AS1411 is a DNA aptamer in phase II in AML

DCAMs are inhibitors of wild-type Flt-3 and are being developed for auto-immune diseases

Delivered by Investis and link to website (opens in a new window)